Showing results (2761-2770 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|January 1, 1988
Stimulation of natural killer cytotoxicity by long-term treatment with double-stranded polynucleotides without induction of hyporesponsivenessD Nolibe, M N Thang
Cancer Immunology, Immunotherapy : CII|June 24, 2021
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, Sofia Lampaki, Georgia-Angeliki Koliou, et al.
Cancer Immunology, Immunotherapy : CII|June 24, 2021
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibodyHaiqing Ni, Lei Cao, Zhihai Wu, et al.
Cancer Immunology, Immunotherapy : CII|June 26, 2021
Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysisGilbert Lazarus, Refael Alfa Budiman, Ikhwan Rinaldi
Cancer Immunology, Immunotherapy : CII|December 19, 2022
CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphomaJeong Ryeol Kim, Donghyuk Lee, Yerim Kim, et al.
Cancer Immunology, Immunotherapy : CII|November 27, 2022
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancerYoshinori Kajiwara, Hiroshi Tazawa, Motohiko Yamada, et al.
Cancer Immunology, Immunotherapy : CII|November 30, 2022
Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancersPiera Filomena Fiore, Anna Laura Di Pace, Libenzio Adrian Conti, et al.
Cancer Immunology, Immunotherapy : CII|December 15, 2022
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patientsBangwei Fang, Yu Wei, Hao Zeng, et al.
Cancer Immunology, Immunotherapy : CII|December 6, 2022
CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancerLei Wu, Shengnan Sun, Fei Qu, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2022
Combination of magnetic hyperthermia and immunomodulators to drive complete tumor regression of poorly immunogenic melanomaAmi Nishikawa, Yutaro Suzuki, Masahiro Kaneko, et al.
Pageof 652